Beck Capital Management LLC Cuts Position in Humana Inc. (NYSE:HUM)

Beck Capital Management LLC trimmed its stake in Humana Inc. (NYSE:HUM) by 3.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,378 shares of the insurance provider’s stock after selling 84 shares during the period. Beck Capital Management LLC’s holdings in Humana were worth $1,155,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in HUM. Price T Rowe Associates Inc. MD lifted its position in shares of Humana by 12.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,623,130 shares of the insurance provider’s stock valued at $3,904,491,000 after buying an additional 831,057 shares during the last quarter. FMR LLC lifted its position in Humana by 7.1% during the first quarter. FMR LLC now owns 7,342,938 shares of the insurance provider’s stock valued at $3,564,703,000 after acquiring an additional 486,893 shares during the last quarter. GQG Partners LLC lifted its position in Humana by 4.5% during the first quarter. GQG Partners LLC now owns 2,243,042 shares of the insurance provider’s stock valued at $1,088,907,000 after acquiring an additional 96,896 shares during the last quarter. Geode Capital Management LLC boosted its stake in Humana by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 2,217,785 shares of the insurance provider’s stock valued at $1,133,529,000 after acquiring an additional 49,839 shares in the last quarter. Finally, Morgan Stanley grew its holdings in Humana by 20.8% in the fourth quarter. Morgan Stanley now owns 1,688,442 shares of the insurance provider’s stock worth $864,804,000 after purchasing an additional 290,865 shares during the last quarter. 91.86% of the stock is currently owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of NYSE:HUM traded down $4.25 during trading on Friday, reaching $467.73. 910,018 shares of the company’s stock traded hands, compared to its average volume of 801,681. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.58. Humana Inc. has a fifty-two week low of $423.29 and a fifty-two week high of $571.30. The company has a 50-day simple moving average of $465.41 and a 200-day simple moving average of $488.01. The firm has a market cap of $57.96 billion, a PE ratio of 17.45, a P/E/G ratio of 1.22 and a beta of 0.66.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $8.94 EPS for the quarter, beating the consensus estimate of $8.88 by $0.06. The company had revenue of $26.75 billion for the quarter, compared to analyst estimates of $25.83 billion. Humana had a return on equity of 20.70% and a net margin of 3.42%. Humana’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period last year, the company earned $8.67 earnings per share. As a group, analysts predict that Humana Inc. will post 28.25 earnings per share for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 29th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 0.76%. The ex-dividend date is Thursday, September 28th. Humana’s payout ratio is presently 13.21%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HUM. Barclays decreased their price objective on Humana from $620.00 to $585.00 in a report on Monday, June 19th. Morgan Stanley lowered their price target on Humana from $637.00 to $624.00 and set an “overweight” rating for the company in a report on Wednesday, August 30th. Argus downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Friday, June 23rd. Stephens increased their price objective on shares of Humana from $555.00 to $560.00 and gave the company an “overweight” rating in a research report on Thursday, August 3rd. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Humana from $468.00 to $628.00 and gave the stock a “buy” rating in a research report on Monday, August 7th. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $592.30.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.